Bharat Biotech submitted the data of phase 3 trials to Drug Controller General of India (DGCI) over the weekend. The data will be studied by a panel of experts today before Bharat Biotech meets up with World Health Organization (WHO).

The made in India Covaxin data will be reviewed today after which the efficacy of Covaxin is likely to be established. The DGCI had granted permission to Bharat Biotech for emergency use of Covaxin based on the 1st and 2nd clinical trials. The trials comprised of about 680 participants.

Once the efficacy of Covaxin is established, the recipients will be able to travel abroad. It may be noted that entries for Covaxin recipients have been denied by a lot of countries. Bharat Biotech had earlier stated that it would make phase 3 trial data public by July following which the manufacturer company will apply for a full licensure for covid vaccine in India.  

Once Bharat Biotech gets a nod from WHO, the approval will prove to be more of a boon for those who have been administered with Covaxin. The disapproval of this vaccine has been causing quite a havoc as many students and those working abroad have also been given Covaxin jabs and it is time for them to get back to their educational institutes and jobs.

(media reports)